India, June 12 -- BioCryst Pharmmaceuticals Inc. (BCRX), a biotechnology company, on Friday released new data from the real-world APeX-P study for ORLADEYO and the Phase 1b/2 ALPHA-STAR for Navenibart in treating hereditary angioedema.
ORLADEYO (berotralstat) is an oral prophylactic therapy that increases plasma kallikrein to treat hereditary angioedema (HAE), and received approval for the same from the U.S. Food and Drug Administration (FDA) in 2020.
The APeX-P trial is an ongoing, open-label study evaluating ORLADEYO as a once-daily dose over 48 weeks in patients with HAE due to a C1-inhibitor deficiency.
Results indicated that ORLADEYO- treated patients had 0.169 HAE attacks per month, compared to 0.691 HAE attacks while on standard-o...